NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,035 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	Eloralintide	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2025-12-15
• Primary completion: 2028-01-01
• Completion: 2028-02-01
• First posted: 2025-12-15
• Last updated: 2026-04-17

Locations

159 sites across 14 countries: United States, Argentina, China, Czechia, Germany, India, Japan, Mexico, Poland, Puerto Rico, Slovakia, South Korea, Spain, Taiwan

Regulatory

• FDA-regulated drug study